BioNTech Analyst Breaks Down Coronavirus Vaccine Readout Timeline, , on October 14, 2020 at 4:53 pm

Financial News
By
On October 14, 2020
In Financial News
Tags:

The Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) combo has flagged an October timeline for the release of the first two interim events from its Phase 2/3 study of the coronavirus vaccine candidate BNT162b2. An analyst at SVB Leerink said a push backward to November shouldn’t matter, and here’s why.The BioNTech Analyst: Daina Graybosch reiterated a Market Perform rating on BioNTech and raised the price target from $62 to $69.The BioNTech Thesis: If Pfizer and BioNTech do not release the first interim readout by October, it likely means the independent, external data monitoring committee decided to continue the study through the first two interim analyses, Graybosch said in a Wednesday note.Most investors are expecting an early positive result in October, the analyst said. They have not factored in stopping with efficacy at the upper bound of expectations coming with interim analysis or DMC decisions later than October, she said.Related Link: The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline The BNT162b2 trial continuing to November without an announcement does not mean the vaccine efficacy will fall short of high expectations, Graybosch said.First, the number of events for the first two interim analyses is small enough that shifting epidemiology of infection could delay the readouts, the analyst said. Second, even if the vaccine is quite effective at preventing symptomatic diseases with, for example, 70% efficacy, the probability of the trial showing this result — thereby statistically meeting a positive stopping boundary — is low to moderate, she said. The DMC is not bound to stop the study, even if the positive stopping rules have been met, as the protocol makes clear that efficacy and futility boundaries will be applied in a nonbinding way, Graybosch said. “We are increasingly confident that BNT162b2 will prove efficacious in its primary endpoint of preventing symptomatic disease, given alignment of murine, non-human primate, immunogenicity (neutralizing antibodies [Nabs] and CD8+ T cell), and efficacy from antibody therapies.”Although building public skepticism will likely dampen the uptake of COVID-19 vaccines, SVB Leerink said it has increasing confidence in an annual re-vaccination market and the competitive position of BNT162b2.BNTX, PFE Price Action: At last check, BioNTech shares were down 2.02% to $91.12. Pfizer shares were trading down slightly at $36.88.Related Link: FDA’s COVID-19 Vaccine Guidance Shows ‘Substantial’ Obligations For Developers: Analyst Latest Ratings for BNTX DateFirmActionFromTo Oct 2020SVB LeerinkMaintainsMarket Perform Aug 2020SVB LeerinkMaintainsMarket Perform Aug 2020SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for BNTX View the Latest Analyst Ratings See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Moderna: Coronavirus Vaccine Patents Will Go Unenforced During Pandemic * The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx’s Positive Preannouncement, Aziyo Biologics Debuts On Wall Street(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.,

BioNTech Analyst Breaks Down Coronavirus Vaccine Readout TimelineThe Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) combo has flagged an October timeline for the release of the first two interim events from its Phase 2/3 study of the coronavirus vaccine candidate BNT162b2. An analyst at SVB Leerink said a push backward to November shouldn’t matter, and here’s why.The BioNTech Analyst: Daina Graybosch reiterated a Market Perform rating on BioNTech and raised the price target from $62 to $69.The BioNTech Thesis: If Pfizer and BioNTech do not release the first interim readout by October, it likely means the independent, external data monitoring committee decided to continue the study through the first two interim analyses, Graybosch said in a Wednesday note.Most investors are expecting an early positive result in October, the analyst said. They have not factored in stopping with efficacy at the upper bound of expectations coming with interim analysis or DMC decisions later than October, she said.Related Link: The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline The BNT162b2 trial continuing to November without an announcement does not mean the vaccine efficacy will fall short of high expectations, Graybosch said.First, the number of events for the first two interim analyses is small enough that shifting epidemiology of infection could delay the readouts, the analyst said. Second, even if the vaccine is quite effective at preventing symptomatic diseases with, for example, 70% efficacy, the probability of the trial showing this result — thereby statistically meeting a positive stopping boundary — is low to moderate, she said. The DMC is not bound to stop the study, even if the positive stopping rules have been met, as the protocol makes clear that efficacy and futility boundaries will be applied in a nonbinding way, Graybosch said. “We are increasingly confident that BNT162b2 will prove efficacious in its primary endpoint of preventing symptomatic disease, given alignment of murine, non-human primate, immunogenicity (neutralizing antibodies [Nabs] and CD8+ T cell), and efficacy from antibody therapies.”Although building public skepticism will likely dampen the uptake of COVID-19 vaccines, SVB Leerink said it has increasing confidence in an annual re-vaccination market and the competitive position of BNT162b2.BNTX, PFE Price Action: At last check, BioNTech shares were down 2.02% to $91.12. Pfizer shares were trading down slightly at $36.88.Related Link: FDA’s COVID-19 Vaccine Guidance Shows ‘Substantial’ Obligations For Developers: Analyst Latest Ratings for BNTX DateFirmActionFromTo Oct 2020SVB LeerinkMaintainsMarket Perform Aug 2020SVB LeerinkMaintainsMarket Perform Aug 2020SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for BNTX View the Latest Analyst Ratings See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Moderna: Coronavirus Vaccine Patents Will Go Unenforced During Pandemic * The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx’s Positive Preannouncement, Aziyo Biologics Debuts On Wall Street(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage